Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664109 | 1.00 | MEN1 (0.46) | MEN1KMT2AALDH1A1POLBTDP1 | |
| SCHEMBL10148075 | 0.89 | EGFR (0.48) | MEN1KMT2AALDH1A1POLBTDP1 | |
| SCHEMBL665163 | 0.89 | TDP1 (0.48) | MEN1KMT2AALDH1A1POLBTDP1 | |
| SCHEMBL665162 | 0.89 | TDP1 (0.48) | MEN1KMT2AALDH1A1POLBTDP1 | |
| SCHEMBL664061 | 0.87 | MAPT (0.45) | ALDH1A1TDP1MAPTKDM4EEGFR | |
| SCHEMBL10148066 | 0.87 | MAPT (0.45) | MEN1KMT2AALDH1A1POLBTDP1 | |
| SCHEMBL664060 | 0.87 | MAPT (0.45) | ALDH1A1TDP1MAPTKDM4EEGFR | |
| SCHEMBL662787 | 0.86 | ADORA3 (0.44) | MEN1KMT2AALDH1A1POLBTDP1 | |
| SCHEMBL662786 | 0.86 | ADORA3 (0.44) | MEN1KMT2AALDH1A1POLBTDP1 | |
| SCHEMBL661702 | 0.85 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423182-A1 | DIACYLETHYLENEDIAMINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | MEN1 2222/4885KMT2A 441/4885ALDH1A1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.